The impact on outcome of the number of mutations detected by MS at baseline for CP-CML patients with the T315I mutation. CP-CML patients with T315I by MS were grouped according to the number of mutations detected by MS before commencing ponatinib therapy: T315I alone, n = 43; T315I plus additional mutation(s), n = 20. (A) MCyR. (B) CCyR. (C) MMR. (D) FFS. (E) PFS.